Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

A dose-escalation, randomized, double-blind, placebo-controlled phase 1 clinical trial enrolled 145 eligible participants aged 18–55 years in March 2015 in Liuzhou, China. Stratified by age and sex, the participants were randomly assigned to receive either 30, 60, or 90 μg of the HPV-6/11 vaccine (n...

Повний опис

Бібліографічні деталі
Автори: Zhao-Jun Mo, Zhao-Feng Bi, Wei Sheng, Qi Chen, Teng Huang, Ming-Qiang Li, Xue-Lian Cui, Ya-Hui Wangjiang, Bi-Zhen Lin, Feng-Zhu Zheng, Guang Sun, Ya-Fei Li, Ya Zheng, Si-Jie Zhuang, Ying-Ying Su, Hui-Rong Pan, Shou-Jie Huang, Ting Wu, Jun Zhang, Ning-Shao Xia
Формат: Стаття
Мова:English
Опубліковано: Taylor & Francis Group 2022-11-01
Серія:Human Vaccines & Immunotherapeutics
Предмети:
human papillomavirus
vaccine
genital warts
phase 1 clinical trial
safety
immunogenicity
Онлайн доступ:http://dx.doi.org/10.1080/21645515.2022.2092363

Інтернет

http://dx.doi.org/10.1080/21645515.2022.2092363

Схожі ресурси